Key result
Novel indole derivative Compound 34 shows promising anti-arrhythmic effects and favorable safety in early studies.
Why the study?
The Kv1.5 potassium channel is a promising target for treating atrial fibrillation, and hERG potassium channel kinetics are linked to arrhythmia and sudden death.
A newly synthesized indole-3-carboxylic acid derivative (compound 34) demonstrates promising antiarrhythmic activity and safety in preclinical models, targeting hERG and Kv1.5 channels.
Should not change arrhythmia care; hypothesis-generating for indole derivatives as antiarrhythmics.
The hERG (human ether-à-go-go-related gene) potassium channel has elicited intense scientific interest due to its counter-intuitive kinetics and its association with arrhythmia and sudden death. Kv1.5 potassium channel, encoded by KCNA5, is a promising target for the treatment of atrial fibrillation, one of the common arrhythmia. A new indole derivatives were synthesized via reaction of indole-3-carboxylic acid with 4-[2-(diethylamino)ethoxy]aniline under peptide coupling protocol in DMF with good yields and evaluated their antiarrythmic activity. Among them, 2-butyl- N -{4-[2-(diethylamino)ethoxy]phenyl}-1-(2-fluorobenzoyl)-1 H -indole-3-carboxamide 34 showed preferable anti-arrhythmic effects and favoured safety. These results indicate that lead compound can be a promising antiarrythmic drug for further studies.
No takes yet. Share an insight, caveat, or question.
Platonova et al. (2023) studied Arrhythmia. 2-butyl-N-{4-[2-(diethylamino)ethoxy]phenyl}-1-(2-fluorobenzoyl)-1H-indole-3-carboxamide 34 was evaluated on Antiarrhythmic activity. Compound 34, a newly synthesized indole derivative, demonstrated preferable anti-arrhythmic effects and favored safety, indicating its potential as a promising lead compound for further studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: